Tyra Biosciences (TYRA) Income towards Parent Company (2020 - 2026)
Quarterly Income towards Parent Company fell 39.64% to -$39.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$131.1 million through Mar 2026, down 35.95% year-over-year, with the annual reading at -$119.9 million for FY2025, 38.7% down from the prior year.
Tyra Biosciences filings provide 7 years of Income towards Parent Company readings, the most recent being -$39.3 million for Q1 2026.
- Income towards Parent Company hit -$39.3 million in Q1 2026 for Tyra Biosciences, down from -$33.8 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$11.9 million in Q1 2023 and bottomed at -$39.3 million in Q1 2026.
- Average Income towards Parent Company over 5 years is -$21.8 million, with a median of -$21.2 million recorded in 2023.
- The largest annual shift saw Income towards Parent Company crashed 252.25% in 2022 before it grew 19.86% in 2023.
- Tyra Biosciences' Income towards Parent Company stood at -$12.9 million in 2022, then plummeted by 77.05% to -$22.8 million in 2023, then dropped by 12.01% to -$25.6 million in 2024, then crashed by 32.31% to -$33.8 million in 2025, then decreased by 16.17% to -$39.3 million in 2026.
- Per Business Quant, the three most recent readings for TYRA's Income towards Parent Company are -$39.3 million (Q1 2026), -$33.8 million (Q4 2025), and -$29.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Tyra Biosciences | 2.03 Bn | 2.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.31 Mn |
| Dec 31, 2025 | -33.83 Mn |
| Sep 30, 2025 | -29.87 Mn |
| Jun 30, 2025 | -28.10 Mn |
| Mar 31, 2025 | -28.15 Mn |
| Dec 31, 2024 | -25.57 Mn |
| Sep 30, 2024 | -24.02 Mn |
| Jun 30, 2024 | -18.70 Mn |
| Mar 31, 2024 | -18.19 Mn |
| Dec 31, 2023 | -22.83 Mn |
| Sep 30, 2023 | -21.15 Mn |
| Jun 30, 2023 | -13.29 Mn |
| Mar 31, 2023 | -11.88 Mn |
| Dec 31, 2022 | -12.90 Mn |
| Sep 30, 2022 | -12.52 Mn |
| Jun 30, 2022 | -15.10 Mn |
| Mar 31, 2022 | -14.83 Mn |
| Dec 31, 2021 | -9.93 Mn |
| Sep 30, 2021 | -6.64 Mn |
| Jun 30, 2021 | -5.51 Mn |
| Mar 31, 2021 | -4.21 Mn |
| Dec 31, 2020 | -3.69 Mn |
| Sep 30, 2020 | -2.34 Mn |